Informed Prostate Cancer Patient Support

This figure shows cumulative incidence curves comparing prostate cancer risk between men taking GLP-1 receptor agonists (GLP-1RA, shown in blue) versus those taking basal insulin (shown in black) over a 12-year follow-up period. It's from the Danish nationwide cohort study. Key Elements: Panel a: Intention-to-Treat Analysis Both groups start at 0% risk and increase over time The curves are very similar, nearly overlapping By 12 years, both groups reach approximately 1.75-2% absolute risk of prostate cancer The shaded areas represent confidence intervals (uncertainty ranges) Patient numbers at risk are shown below, decreasing over time as expected in follow-up studies Panel b: Per-Protocol Analysis This analysis only counts time when patients were actually taking their assigned medication Shows a clearer separation between the two groups The blue line (GLP-1RA) stays notably lower than the black line (basal insulin) By 12 years: Basal insulin group: ~1.25% absolute risk GLP-1R...

Scientists Uncover New Weak Spot in Prostate Cancer Cells, a Game-Changer for Treatment Scientists Discover Molecular "Achilles Heel" That Could Boost Prostate Cancer Treatment International research identifies protective enzymes as new therapeutic targets to overcome drug resistance Scientists have uncovered how prostate cancer cells shield themselves from treatment—and found a way to strip away that protection. The discovery could help doctors overcome one of the biggest challenges in treating advanced prostate cancer: resistance to hormone therapy. An international team from Flinders University in Australia and South China University of Technology has identified two enzymes—PDIA1 and PDIA5—that act as molecular guardians for cancer cells, helping them survive, grow, and resist treatment. The findings were published in October 2025 in the Proceedings of the National Academy of Sciences. How Cancer Cells Protect Themselves The enzymes work by stabilizing the androgen r...

Pluvicto in First-line Hormone-Sensitive Prostate Cancer? New Treatment Shows Promise for Men with Newly Diagnosed Metastatic Prostate Cancer PSMAddition Trial Results Presented at ESMO 2025 What You Need to Know: A major clinical trial has shown that adding a targeted radiation therapy called Pluvicto (lutetium-177 PSMA-617) to standard hormone treatment can slow disease progression in men newly diagnosed with metastatic hormone-sensitive prostate cancer. However, experts are debating whether the benefits outweigh the added side effects until more data becomes available. Understanding the Study The PSMAddition trial enrolled 1,144 men with newly diagnosed or minimally treated metastatic hormone-sensitive prostate cancer whose tumors tested positive for PSMA (prostate-specific membrane antigen). Participants received either standard hormone therapy alone (ADT plus an ARPI such as abiraterone, enzalutamide, apalutamide, or darolutamide) or the same hormone therapy plus Pluvicto a...

AI Pilot Aims to Speed Prostate Cancer Diagnosis Now I'll create a comprehensive article incorporating the Leeds NHS pilot information along with the broader context of AI developments in prostate cancer diagnosis and treatment, with specific attention to US implications. AI Revolution in Prostate Cancer: From Same-Day Diagnosis to Treatment Personalization Leeds NHS Pilot Promises Hours-Long Diagnosis; Multiple AI Tools Already Transforming US Care The frustrating wait between "you might have prostate cancer" and "here's what we know" may soon become obsolete. A groundbreaking NHS pilot launching early 2025 at Leeds Teaching Hospitals promises to compress weeks of diagnostic uncertainty into a single day—part of a broader AI revolution already reshaping prostate cancer care on both sides of the Atlantic. The Leeds Breakthrough: One-Day Diagnosis The NHS pilot uses an AI system called Pi, developed by Lucida Medical, to analyze MRI scans in real-time wi...

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease PROSTest Shows 97% Accuracy in Detection—But Questions Remain About Long-Term Surveillance Applications Men navigating prostate cancer screening and treatment decisions may soon have access to a more accurate blood test that could reduce unnecessary biopsies while catching cancer more reliably than PSA. However, while the technology shows impressive initial results, critical questions remain about its use for active surveillance and monitoring after treatment. A prospective study of 105 men in Poland, published recently in The Prostate , found that a novel blood test called PROSTest dramatically outperformed standard PSA testing in detecting prostate cancer. The results were striking: 97% sensitivity, 96% specificity, and an area under the curve (AUROC) of 0.99 compared to PSA's 0.61. "While PSA is useful for identifying men at risk, its low s...